首页> 外文期刊>Japanese circulation journal >Effect of diadenosine tetraphosphate (AP4A) on coronary arterial microvessels in the beating canine heart.
【24h】

Effect of diadenosine tetraphosphate (AP4A) on coronary arterial microvessels in the beating canine heart.

机译:四磷酸腺苷(AP4A)对跳动犬心脏中冠状动脉微血管的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

Diadenosine tetraphosphate (AP4A) can be released from activated platelets and the present study examined its effect on coronary arterial microvessels. The role of purinoceptors in the coronary microcirculation in vivo was also investigated. In open chest dogs, coronary arterioles were observed using a microscope with a floating objective. In Protocol 1, AP4A (1, 10, 100 and 1,000 micromol/L) was superfused onto the heart surface before and during the superfusion of 10 micromol/L of 8-phenyltheophylline (8-PT), a P1 purinoceptor blocker. In Protocol 2, AP4A (0.1, 1, 10, and 100 nmol x kg(-1) x min(-1)) was infused into the left anterior descending coronary artery before and during the superfusion of 10 micromol/L of 8-PT. In addition to 8-PT, 30 micromol/L of pyridoxalphosphate-6-azophenyl 2',4'-disulphonic acid (PPADS), a P2X purinoceptor blocker in Protocol 3, or 300 micromol/L of N(omega)-nitro-L-arginine (LNNA) in Protocol 4, was continuously superfused, and 4 doses of AP4A were cumulatively superfused as in Protocol 1. In Protocol 5, 10 micromol/L of alpha,beta-methylene ATP, an agonist of P2X purinoceptors, was superfused for 60 min. Superfused AP4A dilated arterioles in a dose-dependent manner. The magnitude of dilatation was greater in smaller arterioles (small vessel < or = 150 microm: 24.5+/-2.2% vs large vessel > 150 microm: 10.6+/-1.5% at a dose of 1,000 micromol/L, p<0.001). On the other hand, intraluminally applied AP4A also dilated arterioles, but no size dependency was shown. In the presence of 8-PT, vasodilatory responses to superfused and intraluminally applied AP4A were attenuated and the lower doses of AP4A constricted arterioles. This vasoconstrictor effect was not affected by PPADS. The vasodilatory effect of the higher doses of AP4A was almost abolished in the presence of LNNA. Alpha,beta-methylene ATP had no effect on coronary microvascular diameters. AP4A has bidirectional effects on coronary arterial microvessels: vasodilatory effects mediated by P1 purinoceptors and NO, which might be mediated by P2Y purinoceptors, and a vasoconstrictor effect, which is not mediated by P2X purinoceptors.
机译:可以从活化的血小板中释放出四磷酸腺苷(AP4A),本研究检查了其对冠状动脉微血管的作用。还研究了嘌呤受体在体内冠状动脉微循环中的作用。在开放式胸犬中,使用具有浮动物镜的显微镜观察冠状小动脉。在方案1中,在10μmol/ L的P1嘌呤受体阻滞剂8-苯基茶碱(8-PT)灌注之前和期间,将AP4A(1、10、100和1,000 micromol / L)灌注到心脏表面。在方案2中,在10 micromol / L的8升/升灌流期间和之前,将AP4A(0.1、1、10和100 nmol x kg(-1)x min(-1))注入左冠状动脉前降支。 PT。除了8-PT以外,协议3中的P2X嘌呤受体阻滞剂还包括30 micromol / L的吡ido草磷酸6-偶氮苯基2',4'-二磺酸(PPADS),或300 micromol / L的N(ω)-硝基-如方案1所述,对方案4中的L-精氨酸(LNNA)进行持续融合,并累计融合4剂AP4A。在方案5中,将P2X嘌呤受体的激动剂α,β-亚甲基ATP的10μmol/ L加入到该溶液中。融合60分钟超融合AP4A以剂量依赖性方式扩张小动脉。在较小的小动脉中,扩张幅度更大(在1,000 micromol / L的剂量下,小于或等于150微米的小血管:24.5 +/- 2.2%,与大于150微米的大血管:10.6 +/- 1.5%,p <0.001) 。另一方面,腔内施用的AP4A也使小动脉扩张,但未显示尺寸依赖性。在存在8-PT的情况下,对融合和管腔内应用的AP4A的血管舒张反应减弱,而较低剂量的AP4A收缩小动脉。这种血管收缩作用不受PPADS影响。在存在LNNA的情况下,更高剂量的AP4A的血管舒张作用几乎消失了。 α,β-亚甲基ATP对冠状动脉微血管直径没有影响。 AP4A对冠状动脉微血管具有双向作用:P1嘌呤受体和NO介导的血管舒张作用可能由P2Y嘌呤受体介导,而血管收缩作用却不受P2X嘌呤受体介导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号